logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11446263 B1

PDFFull Text
Date of Patent:
Sep. 20, 2022

Filed:

Dec. 22, 2016

Caspase inhibitor-containing drug for treating or preventing disorders caused by tgf-β, and applications thereof

Applicant:

The Doshisha, Kyoto, JP;

Inventors:

Noriko Koizumi, Kyoto, JP;

Naoki Okumura, Kyoto, JP;

Assignee:

The Doshisha, Kyoto, JP;

Attorney:

Marshall, Gerstein & Borun LLP

Primary Examiner:

Sun Jae Yoo

Int. Cl.
CPC ...
A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 31/122 (2006.01); A61K 31/4725 (2006.01); A61K 31/165 (2006.01); A61K 31/197 (2006.01); A61K 45/06 (2006.01); A61P 27/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/165 (2013.01); A61K 31/122 (2013.01); A61K 31/4725 (2013.01); A61P 27/02 (2018.01);
Abstract

Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Find Patent Forward Citations

Loading…